Baillie Gifford & CO Bio N Tech Se Transaction History
Baillie Gifford & CO
- $126 Billion
- Q1 2024
A detailed history of Baillie Gifford & CO transactions in Bio N Tech Se stock. As of the latest transaction made, Baillie Gifford & CO holds 8,358,939 shares of BNTX stock, worth $672 Million. This represents 0.61% of its overall portfolio holdings.
Number of Shares
8,358,939
Previous 8,689,182
3.8%
Holding current value
$672 Million
Previous $917 Million
15.91%
% of portfolio
0.61%
Previous 0.74%
Shares
13 transactions
Others Institutions Holding BNTX
# of Institutions
326Shares Held
40.4MCall Options Held
1.31MPut Options Held
1.37M-
Primecap Management CO Pasadena, CA4.81MShares$386 Million0.34% of portfolio
-
Harding Loevner LP Bridgewater, NJ3.82MShares$307 Million2.24% of portfolio
-
Flossbach Von Storch Ag Cologne, 2M3.47MShares$279 Million1.4% of portfolio
-
Temasek Holdings (Private) LTD Singapore, U03.43MShares$276 Million1.76% of portfolio
-
Black Rock Inc. New York, NY1.91MShares$153 Million0.0% of portfolio
About BioNTech SE
- Ticker BNTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 242,684,992
- Market Cap $19.5B
- Description
- BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...